NEURACAP
Sector OutlookPublished · 22 pages · Free to read

Oncology Therapeutics Sector Outlook — September 2026

An Oncology Therapeutics sector outlook covering business segments, EV / Revenue (CY2027E) valuation, precedent transactions and strategic implications, for investors and corporate development teams assessing where clinical evidence and commercial durability drive value, as of September 2026.

For information only. Not an appraisal or a fairness opinion.

What moved since: Oncology Therapeutics M&A update, 14–28 September 2026

Key figures

Premium-end EV / Revenue (CY2027E)
19.5x
Highest-rated cohort
Discount-end EV / Revenue (CY2027E)
1.7x
Lowest-rated cohort
Sector median EV / Revenue (CY2027E)
3.5x
31 rated companies
Clinical-stage share of universe
94%
51 of 54 companies

Read the report

NeuraCap

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › ONCOLOGY THERAPEUTICS

Oncology Therapeutics: Promise and Proof Split Value

The report shows how development stage, franchise durability and clinical evidence shape market positioning.

September 2026 · Prepared by NeuraCap AI · Confidential

Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E)

Oncology Therapeutics Coverage | September 2026 | Confidential | Not investment advice

1

1 / 22

Executive summary

Oncology Therapeutics splits between scaled, commercial-stage franchises and a clinical-stage majority still building toward approval. On the primary EV / Revenue (CY2027E) basis, valuation ranges from 19.5x at the premium end to 1.7x at the discount end against a 3.5x sector median, and forecast growth alone does not explain that spread. The pattern is associated with differences in clinical evidence, franchise durability and confidence in forward revenue, pointing owners and boards toward evidence, funding discipline and commercial execution as the levers that matter most.

Key findings

  • Clinical-stage developers make up 94% of the oncology universe.
  • Valuation spans 19.5x at the premium end to 1.7x at the discount end.
  • Forward revenue (EV / Revenue) is the sector's workable common lens.
  • Faster forecast growth does not reliably command a higher multiple.

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › ONCOLOGY THERAPEUTICS

    This is the cover page for the Oncology Therapeutics sector outlook, with market data as of September 28, 2026.

    We're opening the Oncology Therapeutics sector outlook, valued primarily on EV / Revenue for CY2027E as of September 28, 2026. The pages that follow build the case for where the market is placing its bets.

    Everything on this page

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › ONCOLOGY THERAPEUTICS Oncology Therapeutics: Promise and Proof Split Value The report shows how development stage, franchise durability and clinical evidence shape market positioning. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E) Oncology Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    CONTENTS

    What This Report Covers

    This page outlines the five report sections plus appendix, starting with the bottom line.

    We've structured this report so the bottom line comes first: even a reader who only reads section one leaves with the full story. From there we move through the market landscape, valuation and situations, precedent transactions and strategic implications, with the full company detail held in the appendix. This sequencing lets you go as deep as you need, so the headline conclusion is never buried.

    Everything on this page

    CONTENTS What This Report Covers 01 The Bottom Line Oncology Value Splits Between Scaled Franchises and Clinical-Stage Promise 02 The Landscape Clinical-Stage Developers Define the Field, While Scaled Franchises Provide the Commercial Benchmark 03 Valuation & Situations Forward Revenue Pricing Rewards More than Near-Term Growth 04 Precedent Transactions Precedent Transactions Show Buyers Committing Across Development Stages 05 Strategic Implications Clinical Evidence, Capital Discipline and Commercial Durability Define the Next Value Step 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Oncology Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2

  3. 03
    01 · THE BOTTOM LINE

    Oncology Therapeutics Splits Between Scaled Franchises and Clinical-Stage Promise

    This page summarizes the report's core finding: Oncology Therapeutics splits between scaled franchises and clinical-stage promise.

    We price this sector primarily on EV / Revenue for CY2027E, the basis with the strongest coverage across the universe. Clinical-stage developers dominate the field, and the valuation range between the highest- and lowest-priced names is wide, which tells us the market is discriminating hard on evidence and durability rather than treating oncology as one uniform trade. That split is the lens for everything else in this report, so it's worth holding in mind as we move into the market map.

    Everything on this page

    01 · THE BOTTOM LINE Oncology Therapeutics Splits Between Scaled Franchises and Clinical-Stage Promise The full story on one page · figures on EV / Revenue (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (31 of 54 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (33 of 54 companies), so this report follows it. Qualitative characterisations are NeuraCap views. Oncology Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 Forward Revenue Is the Practical Common Lens 31 of 54 companies carry a CY2027E EV / Revenue estimate, while only 6 of 54 have meaningful EBITDA. A forward multiple already credits forecast growth, so a premium that survives this lens signals expected durability. 2 Clinical-Stage Value Sits Alongside Evidence and Optionality Clinical-stage oncology drug developers represent 51 of 54 companies and 94% of the set. Their standing sits alongside registrational clarity, survival evidence, biomarker selection and cash runway to the next pivotal readout. 3 The Two Ends Carry Very Different Expectations The premium end is valued at 19.5x, compared with 1.7x at the discount end. That spread is associated with differences in development maturity, franchise durability and confidence in forecast revenue. 4 Faster Forecast Growth Does Not Consistently Sit with Higher Pricing Companies above the 15% growth split are valued at 3.2x, compared with 4.2x below it, across 12 names in each group. The observed pattern leaves clinical quality, timing and revenue durability central to the valuation discussion. 3.5x Sector median EV/Revenue CY2027E consensus · EV/Revenue is the lens because practitioners price this growth set on revenue and 3 of 54 names are… 19.5x Premium end EV/Revenue vs 1.7x at the discount end top quartile (n=8) against bottom quartile (n=8) on EV/Revenue — the spread the report explains 28 Transactions with disclosed terms 86 recorded in this tier · 3 told as case studies, the full list in the appendix

  4. 04
    SECTION 02

    02

    This is a section divider introducing the market map of clinical-stage developers versus scaled franchises.

    Development stage changes the evidence, capital and valuation framework that applies, so we group the universe by business segment next.

    Everything on this page

    SECTION 02 02 THE LANDSCAPE Clinical-Stage Developers Define the Field, While Scaled Franchises Provide the Commercial Benchmark Development stage changes the evidence, capital and valuation framework that matters. 02 of 06 Oncology Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4

  5. 05
    02 · MARKET MAP

    Clinical-Stage Developers Dominate the Field, but Commercial Models Anchor the Benchmarks

    This page groups all 54 companies by business segment and shows the median EV / Revenue (CY2027E) for each group.

    We've grouped the approved universe by business segment and compared median EV / Revenue on a CY2027E basis across groups. Clinical-stage developers dominate the count, but the scaled, commercial-stage names set the benchmark the market uses to judge everyone else. That contrast is the starting point for how we read valuation across the rest of the sector.

    Everything on this page

    02 · MARKET MAP Clinical-Stage Developers Dominate the Field, but Commercial Models Anchor the Benchmarks 54 approved companies grouped by business segment · median EV / Revenue (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Oncology Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 CLINICAL-STAGE ONCOLOGY DRUG DEVELOPERS 51 cos median 3.9x Revolution (RVMD) BeOne Medicines (ONC) Incyte (INCY) Exelixis (EXEL) Cogent Biosciences (COGT) Celcuity (CELC) Relay Therapeutics (RLAY) Tango Therapeutics (TNGX) IDEAYA Biosciences (IDYA) Zai Lab Limited (ZLAB) Enliven (ELVN) Immunome (IMNM) Nanobiotix S.A. (NBTX) Syndax (SNDX) Inhibrx (INBX) +36 more Pipeline value depends on probability of success, registrational design and runway to the next clinical catalyst. LARGE-CAP DIVERSIFIED ONCOLOGY FRANCHISES 2 cos median 5.1x Amgen (AMGN) Bristol-Myers (BMY) Scaled portfolios provide a reference for durable revenue, profitability and reinvestment capacity. COMMERCIAL-STAGE SPECIALTY ONCOLOGY AND SUPPORTIVE CARE 1 cos 1.6x · 1 rated HUTCHMED (China) (HCM) Commercial execution, guideline positioning and franchise durability shape the relevant revenue benchmark.

  6. 06
    02 · LANDSCAPE

    What the Market Underwrites Tracks with Development Stage

    This page shows that what the market pays for tracks closely with each company's development stage.

    Segment medians on EV / Revenue for CY2027E line up with where each group sits in development, from earliest-stage science to approved, revenue-generating franchises. The company-level detail behind these medians sits in the appendix for anyone who wants to trace an individual name. For a client, this means development stage is the first filter to apply before comparing any two companies on multiple alone.

    Everything on this page

    02 · LANDSCAPE What the Market Underwrites Tracks with Development Stage Segment view of the approved universe · EV / Revenue (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Oncology Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/Revenue Names to know What they do — and why it matters Clinical-stage oncology drug developers 51 94% 3.9x Revolution Medicines, Inc. (RVMD) · BeOne Medicines AG (ONC) · +49 more Evidence carries the value. These businesses are primarily assessed asset by asset, with weight placed on probability of success, registrational clarity, survival benefit and the funding path to the next readout. Large-cap diversified oncology franchises 2 4% 5.1x Amgen Inc. (AMGN) · Bristol-Myers Squibb Company (BMY) Scale supports durability. Established portfolios combine marketed revenue, operating cash flow and multiple clinical programs, allowing investors to assess franchise resilience alongside pipeline renewal. Commercial-stage specialty oncology and supportive care 1 2% 1.6x n=1 HUTCHMED (China) Limited (HCM) Execution follows approval. Value depends on uptake, guideline inclusion, pathway positioning and the cost required to establish durable share after regulatory clearance.

  7. 07
    SECTION 03

    03

    This is a section divider introducing forward revenue valuation and what drives it beyond near-term growth.

    The valuation range points to real differences in clinical maturity, franchise durability and estimate confidence, so we open the multiple up next.

    Everything on this page

    SECTION 03 03 VALUATION & SITUATIONS Forward Revenue Pricing Rewards More than Near-Term Growth The range points to meaningful differences in clinical maturity, franchise durability and estimate confidence. 03 of 06 Oncology Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7

  8. 08
    03 · PUBLIC MARKET VALUATION

    The Valuation Range Separates Durable Expectations from Execution Risk

    This page ranks the 12 highest- and 12 lowest-valued of 31 rated companies on EV / Revenue (CY2027E) against a sector median of 3.5x.

    Across the rated companies, EV / Revenue on a CY2027E basis ranges from 19.5x at the top to 1.7x at the bottom, against a sector median of 3.5x. That spread separates names the market treats as durable from names still carrying execution risk, with the mid-cohort clustering close to the median. For a client, the width of this range is itself the signal: it shows how much conviction the market wants before a name earns the premium tier.

    Everything on this page

    03 · PUBLIC MARKET VALUATION The Valuation Range Separates Durable Expectations from Execution Risk EV / Revenue (CY2027E) · the 12 highest and 12 lowest of 31 rated companies · sector median 3.5x · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (31 of 54 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (33 of 54 companies), so this report follows it. The 7 mid-cohort names cluster near the median; the full set is in the appendix and companion tables. Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / Revenue (CY2027E) basis. Panel commentary is a NeuraCap view. Oncology Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM END — FORWARD REVENUE EXPECTATIONS · median 19.5x DISCOUNT END — EXECUTION AND DURABILITY QUESTIONS · median 1.7x Sector median 3.5x WHAT SEPARATES THE TWO ENDS The top carries conviction. The premium end is valued at 19.5x on CY2027E revenue, indicating high expectations for future revenue durability despite the forward lens already crediting forecast growth. The bottom carries questions. The discount end is valued at 1.7x, a level associated with greater uncertainty around commercial uptake, development outcomes or franchise duration. Clinical context still matters. Revenue multiples cannot capture differences in line of therapy, registrational design, biomarker selection or remaining exclusivity. Those attributes remain important when comparing names across the range.

  9. 09
    03 · VALUATION DRIVERS

    Forecast Growth Alone Does Not Separate Higher-Valued Oncology Companies

    This page compares median EV / Revenue (CY2027E) across revenue-growth cohorts split at the covered median growth rate.

    Companies above the growth split trade at 3.2x versus 4.2x below it, each cohort covering 12 names. Forecast growth alone does not explain who commands the higher multiple in this sample. That pattern keeps clinical quality, timing and revenue durability central to the valuation conversation, so growth alone isn't a sufficient story for a client underwriting these names.

    Everything on this page

    03 · VALUATION DRIVERS Forecast Growth Alone Does Not Separate Higher-Valued Oncology Companies Median EV / Revenue (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=12; slower n=12; higher-margin n=0; lower-margin n=0). Driver readings are NeuraCap views on the supplied data — association, not causation. Oncology Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/Revenue, median per cohort · growth split at 15% · EBITDA-margin split at n/a Higher Forecast Growth Sits with the Lower Observed Multiple Across 12 companies above the 15% growth split, the valuation is 3.2x. The 12 companies below the split are valued at 4.2x, showing that growth and pricing do not move together consistently in this sample. Clinical Quality Changes the Meaning of Revenue A forecast backed by a clean registrational path, survival evidence and a biomarker-selected population carries a different risk profile from revenue dependent on an early program or uncertain uptake. Runway Affects the Path to the Next Catalyst Financing capacity matters when pivotal readouts, confirmatory work or launch investment sit beyond current resources. The strategic question is whether capital reaches the next evidence point without narrowing development options.

  10. 10
    03 · SITUATION MAP

    Four Positions Reveal Where Expectations and Growth Diverge

    This page maps rated companies on EV / Revenue versus the sector median against revenue growth versus the covered median, forming four positions.

    We cut the rated set on EV / Revenue against the 3.5x sector median and on revenue growth against the 15% covered median, producing four positions where expectations and growth diverge. Some names carry growth without the multiple to match, and others carry the multiple without matching growth, which is where the real underwriting questions sit. This is an observation of where the market's expectations diverge from the fundamentals shown, not a recommendation, so it's a useful bridge into the next section on strategic paths.

    Everything on this page

    03 · SITUATION MAP Four Positions Reveal Where Expectations and Growth Diverge Cut on EV / Revenue vs the sector median (3.5x) (rows) and revenue growth vs the covered median (15%) (columns) · 7 rated names without the second measure are not mapped · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Oncology Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Higher Value, Higher Growth Above-median multiple · above-median revenue growth 4 names BeOne Medicines AG (ONC) · Zai Lab Limited (ZLAB) · Nuvation Bio Inc. (NUVB) · +1 more Four companies combine above-midpoint valuation with above-midpoint revenue growth. Their next test is whether clinical progress and commercial execution can sustain those expectations. Higher Value, Lower Growth Above-median multiple · below-median revenue growth 7 names Amgen Inc. (AMGN) · Bristol-Myers Squibb Company (BMY) · Exelixis, Inc. (EXEL) · +4 more Seven companies carry above-midpoint valuation despite below-midpoint revenue growth. Franchise durability, pipeline optionality or confidence in future catalysts may sit alongside that positioning. Lower Value, Higher Growth Below-median multiple · above-median revenue growth 8 names Syndax Pharmaceuticals, Inc. (SNDX) · HUTCHMED (China) Limited (HCM) · Geron Corporation (GERN) · +5 more Eight companies pair above-midpoint growth with below-midpoint valuation. The gap points to questions around revenue quality, clinical durability, capital needs or the credibility of the forecast. Lower Value, Lower Growth Below-median multiple · below-median revenue growth 5 names Incyte Corporation (INCY) · Immunocore Holdings plc (IMCR) · Puma Biotechnology, Inc. (PBYI) · +2 more Five companies sit below both midpoints. Strengthening clinical evidence, focusing capital and improving the path to durable revenue are the central operating considerations.

  11. 11
    03 · THE AGENDA

    Three Paths Show up in the Set: Core Growth, Added Scale, and a Mix Tilted Toward What Buyers Pay up For

    This page frames three paths that appear in the data: core growth, added scale, and a mix weighted toward what buyers pay up for.

    The situation map points to three recurring paths across the set: doubling down on core growth, adding scale, or shifting the mix toward the traits the market pays up for. We frame these as the questions an owner or acquirer should be resolving, grounded in the cohort data shown earlier rather than as a recommendation to act. That framing carries directly into how we read the precedent transactions next.

    Everything on this page

    03 · THE AGENDA Three Paths Show up in the Set: Core Growth, Added Scale, and a Mix Tilted Toward What Buyers Pay up For NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Oncology Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 Concentrate Capital Around Decisive Evidence A focused path to a registrational study or pivotal readout can sharpen the value case while preserving resources for the programs with the clearest clinical and commercial role. What changes the answer: The answer changes when probability of success, enrollment timing or cash runway no longer supports the current program mix. Use Partnerships to Preserve Strategic Choice Territory rights, co-development structures and asset-level partnerships can fund development while retaining selected economics and reducing dependence on a single financing route. What changes the answer: The answer changes when external capital can reach a catalyst on better terms than funding the full program internally. Build Commercial Depth Around the Franchise For approved and near-approval assets, guideline positioning, diagnostic access and field execution can strengthen revenue durability beyond regulatory clearance. What changes the answer: The answer changes when uptake, pathway placement or launch cost becomes more important than the next regulatory milestone.

  12. 12
    SECTION 04

    04

    This is a section divider introducing precedent transactions across development stages.

    Buyers are committing capital across development stages, and strategic fit and asset maturity matter alongside the disclosed transaction benchmark, which is the ground we cover next.

    Everything on this page

    SECTION 04 04 PRECEDENT TRANSACTIONS Precedent Transactions Show Buyers Committing Across Development Stages Strategic fit and asset maturity matter alongside the disclosed transaction benchmark. 04 of 06 Oncology Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12

  13. 13
    04 · DEAL CASE STUDIES

    Nine Precedent Transactions Span Strategic Conviction and Stage-Specific Pricing

    This page presents three of 28 disclosed-terms precedent transactions as case studies, with multiples on LTM financials at announcement.

    We've selected three of the disclosed-terms transactions as case studies, each priced on LTM financials at the time of announcement. These deal multiples sit on a different basis than the CY2027E public multiples used elsewhere in this report, so no direct spread is claimed between the two. The full list of transactions is in the appendix, and reading why each deal happened gives a client a grounded sense of what buyers have actually paid for at different stages of development.

    Everything on this page

    04 · DEAL CASE STUDIES Nine Precedent Transactions Span Strategic Conviction and Stage-Specific Pricing 3 of 28 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 97 precedent record(s) carry data-quality flags (deal value unit unresolved; duplicate precedent id; no evidence record); figures are shown as recorded in the filing. 58 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Oncology Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13 Mar-2023 $42.0B Pfizer Inc. acquires Seagen Inc. EV / LTM revenue 21.4x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The transaction suggests a strategic fit between an oncology asset and a buyer able to support further development. The logic rests on adding clinical optionality within an established operating structure. HOW THE TARGET WAS VALUED The precedent is most useful as a strategic benchmark rather than a standalone public-market multiple. Its relevance depends on development stage, retained rights and the capital required to reach the next catalyst. May-2021 $3.6B Genscript Biotech Corporation acquires Legend Biotech Corp EV / LTM revenue 45.7x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The transaction suggests that clinical differentiation and portfolio fit can support buyer interest before a franchise reaches full commercial scale. Registrational clarity and development funding remain central to that reading. HOW THE TARGET WAS VALUED The valuation should be read against the target's development stage and program rights. It represents a transaction benchmark rather than the top of the range for the broader public-company set. Apr-2022 $916M Halozyme Therapeutics, Inc. acquires Antares Pharma, Inc. EV / LTM revenue 5.0x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The transaction suggests that a buyer saw value in combining the target's program with broader development capabilities. The strategic fit is clearest where capital and clinical infrastructure can carry the asset toward a pivotal milestone. HOW THE TARGET WAS VALUED The precedent is relevant to companies with comparable clinical maturity and ownership rights. Public-company comparisons still require adjustment for forecast revenue, funding needs and remaining development risk.

  14. 14
    SECTION 05

    05

    This is a section divider introducing the strategic implications of clinical evidence, capital discipline and commercial durability.

    Management choices can strengthen positioning well before the market reaches a final view, and that is the focus of the section ahead.

    Everything on this page

    SECTION 05 05 STRATEGIC IMPLICATIONS Clinical Evidence, Capital Discipline and Commercial Durability Define the Next Value Step Management choices can strengthen positioning well before the market reaches a final view. 05 of 06 Oncology Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14

  15. 15
    05 · STRATEGIC IMPLICATIONS

    Evidence, Funding and Commercial Execution Show up Together at the Top of the Range

    This page lays out the questions on evidence, funding and commercial execution that this data raises for the next twelve months.

    Evidence, funding and commercial execution tend to show up together at the top of the valuation range, which is the pattern we want a client to test against their own program. We frame this as the open questions the data puts on the table, not as a set of recommendations. Resolving these questions early is what positions a company to move toward the premium end of the range shown earlier in this report.

    Everything on this page

    05 · STRATEGIC IMPLICATIONS Evidence, Funding and Commercial Execution Show up Together at the Top of the Range NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Oncology Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15 FOR OWNERS Protect the Next Value-Defining Milestone Capital allocation is most effective when runway reaches the next decisive clinical or commercial proof point without weakening the programs that create future optionality. FOR MANAGEMENT TEAMS Tie Strategy to Clinical Differentiation Program choices gain weight when they reinforce survival benefit, biomarker selection, combination potential and a clear place in the standard of care. FOR BOARDS Keep Multiple Funding Routes Open Internal development, partnerships and selective portfolio combinations offer different balances of capital, rights and execution risk. The right route depends on runway and the timing of the next catalyst.

  16. 16
    SECTION 06

    06

    This is a section divider introducing the full comparable universe, methodology and sources behind the report.

    Every figure in the body of this report has detail behind it, and this section shows the comparables, the valuation basis and where each underlying disclosure lives.

    Everything on this page

    SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Oncology Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16

  17. 17
    06 · PUBLIC COMPARABLES (1 OF 2)

    Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier

    This page lists public comparables on EV / Revenue (CY2027E) grouped by valuation tier, covering the first portion of the 31 rated companies out of 54 total.

    We've grouped the rated companies by valuation tier, shading each name relative to the 3.5x sector median, alongside the companies without an eligible multiple. Tickers link back to the underlying source so a client can trace any figure to where it originated. This level of detail lets you move from the sector-level read straight to the individual names that matter to you.

    Everything on this page

    06 · PUBLIC COMPARABLES (1 OF 2) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (3.5x); amber marks below · 31 rated companies; 23 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 30 of 31 rated names shown here; the remaining 1 rows are in the companion workbook beside this deck. Names without an eligible multiple are listed in the companion workbook. Oncology Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥6.5x · median 19.5x · 8 companies Aura Biosciences, Inc. AURA Clinical-stage oncology drug developers $297M 60.3x -74% n/a n/a Olema Pharmaceuticals, Inc. OLMA Clinical-stage oncology drug developers $251M 30.6x n/a n/a n/a Nanobiotix S.A. NBTX Clinical-stage oncology drug developers $1.6B 24.9x n/a n/a n/a IDEAYA Biosciences, Inc. IDYA Clinical-stage oncology drug developers $2.7B 23.5x n/a n/a n/a Candel Therapeutics, Inc. CADL Clinical-stage oncology drug developers $674M 15.5x -53% n/a n/a ALX Oncology Holdings Inc. ALXO Clinical-stage oncology drug developers $60M 11.2x 16% n/a n/a Genelux Corporation GNLX Clinical-stage oncology drug developers $87M 11.1x n/a n/a n/a Amgen Inc. AMGN Large-cap diversified oncology franchises $271B 6.7x 4% 45% 48 CORE — 2.1x–6.5x · median 3.5x · 15 companies Monte Rosa Therapeutics, Inc. GLUE Clinical-stage oncology drug developers $360M 6.3x -13% n/a n/a Nuvation Bio Inc. NUVB Clinical-stage oncology drug developers $1.5B 5.3x 42% n/a n/a Immuneering Corporation IMRX Clinical-stage oncology drug developers $116M 5.1x 7% n/a n/a Ascentage Pharma Group International AAPG Clinical-stage oncology drug developers $1.4B 4.9x n/a n/a n/a Exelixis, Inc. EXEL Clinical-stage oncology drug developers $14.2B 4.9x 13% 43% 53 Zai Lab Limited ZLAB Clinical-stage oncology drug developers $2.4B 4.7x 21% n/a n/a BeOne Medicines AG ONC Clinical-stage oncology drug developers $34.7B 4.4x 16% 22% 40

  18. 18
    06 · PUBLIC COMPARABLES (2 OF 2)

    Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier

    This page continues the public comparables list on EV / Revenue (CY2027E) grouped by valuation tier, completing the 31 rated companies out of 54 total.

    This second page completes the comparable set, keeping the same tiering against the 3.5x sector median. Together, both pages give a client the full rated universe in one place, with the ungraded names noted separately. That completeness is what lets any individual comparison be checked against the full distribution shown earlier.

    Everything on this page

    06 · PUBLIC COMPARABLES (2 OF 2) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (3.5x); amber marks below · 31 rated companies; 23 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 30 of 31 rated names shown here; the remaining 1 rows are in the companion workbook beside this deck. Names without an eligible multiple are listed in the companion workbook. Oncology Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 CORE — CONTINUED — 2.1x–6.5x · median 3.5x · 15 companies Bristol-Myers Squibb Company BMY Large-cap diversified oncology franchises $166B 3.5x -3% 38% 35 Syndax Pharmaceuticals, Inc. SNDX Clinical-stage oncology drug developers $1.6B 3.4x 46% n/a n/a Incyte Corporation INCY Clinical-stage oncology drug developers $21.0B 3.4x 5% 14% 40 Fennec Pharmaceuticals Inc. FENC Clinical-stage oncology drug developers $338M 3.3x 42% n/a n/a Verastem, Inc. VSTM Clinical-stage oncology drug developers $577M 3.2x 56% n/a n/a Agenus Inc. AGEN Clinical-stage oncology drug developers $363M 2.6x -1% n/a n/a Immunocore Holdings plc IMCR Clinical-stage oncology drug developers $1.1B 2.4x 8% n/a 15 Innate Pharma S.A. IPHA Clinical-stage oncology drug developers $146M 2.4x 26% n/a n/a DISCOUNT — <2.1x · median 1.7x · 8 companies BridgeBio Oncology Therapeutics Inc. BBOT Clinical-stage oncology drug developers $56M 1.9x n/a n/a n/a Kura Oncology, Inc. KURA Clinical-stage oncology drug developers $385M 1.8x n/a n/a n/a Puma Biotechnology, Inc. PBYI Clinical-stage oncology drug developers $414M 1.8x 1% n/a n/a Geron Corporation GERN Clinical-stage oncology drug developers $612M 1.8x 45% n/a n/a HUTCHMED (China) Limited HCM Commercial-stage specialty oncology and supportive care $1.2B 1.6x 16% n/a n/a Black Diamond Therapeutics, Inc. BDTX Clinical-stage oncology drug developers $4M 1.6x -66% n/a n/a Karyopharm Therapeutics Inc. KPTI Clinical-stage oncology drug developers $166M 0.8x 47% n/a n/a

  19. 19
    06 · PRECEDENT TRANSACTIONS (1 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This page lists precedent transactions with disclosed terms in order from newest, showing 18 of 28 such deals.

    We show a majority of the transactions with disclosed terms, newest first, each priced on LTM financials at the time of announcement. Deal values link back to the underlying filing, and multiples here are not directly comparable to the CY2027E public basis used earlier in this report. Working through these in order gives a client a live sense of how deal terms have moved within the disclosed set.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 28 transactions with disclosed terms in this tier (86 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 97 precedent record(s) carry data-quality flags (deal value unit unresolved; duplicate precedent id; no evidence record); figures are shown as recorded in the filing. 58 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 28 transactions shown; the rest are in the companion workbook. Oncology Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Jun-2026 GSK plc → Nuvalent, Inc. $10.3B n/a n/a The transaction was recorded at $10.3B. Its size suggests substantial strategic conviction in the target's oncology assets and development path. Apr-2026 n/a → Geron Corporation n/a 1.3x n/a The announced transaction was valued at 1.3x revenue. The benchmark sits below the public-company middle of the range. Nov-2025 Merck Sharp & Dohme LLC → Cidara Therapeutics, Inc. $3.2B n/a n/a The announced transaction was recorded at $3.2B. It suggests that buyers can commit meaningful capital where an oncology asset complements an existing development portfolio. Jul-2025 Merck & Co., Inc. → Verona Pharma plc n/a 0.7x n/a The announced transaction was valued at 0.7x revenue. Stage, franchise mix and revenue durability remain important when comparing that figure with oncology peers. Feb-2025 Alumis Inc. → ACELYRIN, Inc. $235M n/a n/a The announced transaction was recorded at $235M. It suggests a route for combining development portfolios and focusing capital across selected programs. Aug-2024 Pharmacosmos A/S → G1 Therapeutics, Inc. n/a 3.4x n/a The announced transaction was valued at 3.4x revenue. The strategic fit points to the relevance of established commercial capabilities when buyers assess marketed oncology products. Feb-2024 XOMA Corporation → Kinnate Biopharma Inc. $55M n/a n/a The announced transaction was recorded at $55M. It illustrates how platform assets and remaining development options can support a transaction at a modest disclosed value. Nov-2023 AbbVie Inc. → ImmunoGen, Inc. n/a 9.9x n/a The announced transaction was valued at 9.9x revenue. The benchmark sits above the public-company middle of the range and indicates high expectations around the target franchise. Jun-2023 Coherus BioSciences, Inc. → Surface Oncology, Inc. $90M 3.0x n/a The completed transaction was recorded at $90M and 3.0x revenue. It shows how an oncology-focused buyer can add a clinical asset at a benchmark close to the public-company middle of the range.

  20. 20
    06 · PRECEDENT TRANSACTIONS (2 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This page continues the list of precedent transactions with disclosed terms, completing the 18 of 28 shown in this report.

    This second page finishes the disclosed-terms list, keeping the same newest-first ordering and LTM-at-announcement basis. The remaining transactions beyond what's shown here sit in the companion materials for anyone who wants the complete record. Together, these two pages are the primary transaction evidence behind the strategic read shown earlier.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 28 transactions with disclosed terms in this tier (86 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 97 precedent record(s) carry data-quality flags (deal value unit unresolved; duplicate precedent id; no evidence record); figures are shown as recorded in the filing. 58 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 28 transactions shown; the rest are in the companion workbook. Oncology Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters May-2023 Pyxis Oncology, Inc. → Apexigen, Inc. $11M n/a n/a Value shown as recorded in the filing; deal value unit unresolved. Mar-2023 Pfizer Inc. → Seagen Inc. $42.0B 21.4x n/a Value shown as recorded in the filing; deal value unit unresolved. Feb-2023 MEI Pharma, Inc. → Infinity Pharmaceuticals, Inc. $11M 4.2x n/a Value shown as recorded in the filing; deal value unit unresolved. Oct-2022 PureTech Health plc → Nektar Therapeutics, Inc. $659M 6.9x n/a Value shown as recorded in the filing; deal value unit unresolved. Jun-2022 Yumanity Therapeutics, Inc. → Kineta, Inc. $21M 4.3x n/a Value shown as recorded in the filing; deal value unit unresolved. Apr-2022 GSK → Sierra Oncology, Inc. n/a 3.2x n/a Apr-2022 Halozyme Therapeutics, Inc. → Antares Pharma, Inc. $916M 5.0x n/a Value shown as recorded in the filing; deal value unit unresolved. Aug-2021 Walgreens Boots Alliance, Inc. → Trillium Therapeutics Inc. n/a 3.1x n/a Jun-2021 Elanco Animal Health Inc → Kindred Biosciences, Inc. $388M 8.8x n/a Value shown as recorded in the filing; deal value unit unresolved.

  21. 21
    06 · METHODOLOGY

    Sources, Assumptions and Data Quality

    Sources, Assumptions and Data Quality.

    Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. 21

    Everything on this page

    06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Oncology Therapeutics Coverage | September 2026 | Confidential | Not investment advice 21 VALUATION BASIS Primary valuation basis: EV / Revenue on CY2027E consensus (31 of 54 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (33 of 54 companies), so this report follows it. EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Oncology Therapeutics and it clears the coverage gate with 31 of 54 companies (57%). P / E is carried as a cross-check. A revenue lens is used rather than a profit multiple because the set is not consistently profitable on a forward basis (6 of 54 names with a meaningful EBITDA). DATA QUALITY & EXCLUSIONS 252 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 1186 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (1185) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.

  22. 22

    The Observed Premium Sits with Durable Expectations, Clinical Clarity and Strategic Choice.

    This is the closing page stating that the observed premium sits with durable expectations, clinical clarity and strategic choice.

    The observed premium in this sector sits with durable expectations, clinical clarity and strategic choice, not with growth or scale alone. The companion tables alongside this deck carry the full universe, the exclusion ledger and the complete source index for any figure a client wants to trace further. That's the standing invitation: use this report as the starting point, and go as deep as the decision in front of you requires.

    Everything on this page

    The Observed Premium Sits with Durable Expectations, Clinical Clarity and Strategic Choice. NeuraCap AI — Oncology Therapeutics Coverage September 2026 · Prepared by NeuraCap AI · Confidential Oncology Therapeutics Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 22

Sources and methodology

This report covers Oncology Therapeutics (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Oncology Therapeutics) with market data and consensus estimates as of September 28, 2026. The company universe is the 54 listed companies whose core business is Oncology Therapeutics according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Ascentage Pharma Group International (AAPG), Actuate Therapeutics Inc (ACTU), Agenus Inc. (AGEN), ALX Oncology Holdings Inc. (ALXO), Amgen Inc. (AMGN), Arvinas, Inc. (ARVN), Aura Biosciences, Inc. (AURA), ArriVent BioPharma, Inc. (AVBP), BridgeBio Oncology Therapeutics Inc. (BBOT), Black Diamond Therapeutics, Inc. (BDTX), Bristol-Myers Squibb Company (BMY), BeyondSpring Inc. (BYSI), Candel Therapeutics, Inc. (CADL), Celcuity Inc. (CELC), Coherus Oncology, Inc. (CHRS), Cogent Biosciences, Inc. (COGT), Corbus Pharmaceuticals Holdings, Inc. (CRBP), Cardiff Oncology, Inc. (CRDF), Enliven Therapeutics, Inc. (ELVN), Exelixis, Inc. (EXEL), Fennec Pharmaceuticals Inc. (FENC), Geron Corporation (GERN), Monte Rosa Therapeutics, Inc. (GLUE), Genelux Corporation (GNLX), HUTCHMED (China) Limited (HCM), IDEAYA Biosciences, Inc. (IDYA), Immunocore Holdings plc (IMCR), Immutep Limited (IMMP), Immunome, Inc. (IMNM), Immuneering Corporation (IMRX), Inhibrx Biosciences Inc. (INBX), Incyte Corporation (INCY), Innate Pharma S.A. (IPHA), Karyopharm Therapeutics Inc. (KPTI), Kura Oncology, Inc. (KURA), Nanobiotix S.A. (NBTX), Nuvation Bio Inc. (NUVB), Nuvectis Pharma, Inc. (NVCT), Olema Pharmaceuticals, Inc. (OLMA), BeOne Medicines AG (ONC), Oncolytics Biotech Inc. (ONCY), ORIC Pharmaceuticals, Inc. (ORIC), Puma Biotechnology, Inc. (PBYI), PMV Pharmaceuticals, Inc. (PMVP), Replimune Group, Inc. (REPL), Relay Therapeutics, Inc. (RLAY), Revolution Medicines, Inc. (RVMD), Syndax Pharmaceutical

Scope and company universe

This report covers Oncology Therapeutics (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Oncology Therapeutics) with market data and consensus estimates as of September 28, 2026. The company universe is the 54 listed companies whose core business is Oncology Therapeutics according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Ascentage Pharma Group International (AAPG), Actuate Therapeutics Inc (ACTU), Agenus Inc. (AGEN), ALX Oncology Holdings Inc. (ALXO), Amgen Inc. (AMGN), Arvinas, Inc. (ARVN), Aura Biosciences, Inc. (AURA), ArriVent BioPharma, Inc. (AVBP), BridgeBio Oncology Therapeutics Inc. (BBOT), Black Diamond Therapeutics, Inc. (BDTX), Bristol-Myers Squibb Company (BMY), BeyondSpring Inc. (BYSI), Candel Therapeutics, Inc. (CADL), Celcuity Inc. (CELC), Coherus Oncology, Inc. (CHRS), Cogent Biosciences, Inc. (COGT), Corbus Pharmaceuticals Holdings, Inc. (CRBP), Cardiff Oncology, Inc. (CRDF), Enliven Therapeutics, Inc. (ELVN), Exelixis, Inc. (EXEL), Fennec Pharmaceuticals Inc. (FENC), Geron Corporation (GERN), Monte Rosa Therapeutics, Inc. (GLUE), Genelux Corporation (GNLX), HUTCHMED (China) Limited (HCM), IDEAYA Biosciences, Inc. (IDYA), Immunocore Holdings plc (IMCR), Immutep Limited (IMMP), Immunome, Inc. (IMNM), Immuneering Corporation (IMRX), Inhibrx Biosciences Inc. (INBX), Incyte Corporation (INCY), Innate Pharma S.A. (IPHA), Karyopharm Therapeutics Inc. (KPTI), Kura Oncology, Inc. (KURA), Nanobiotix S.A. (NBTX), Nuvation Bio Inc. (NUVB), Nuvectis Pharma, Inc. (NVCT), Olema Pharmaceuticals, Inc. (OLMA), BeOne Medicines AG (ONC), Oncolytics Biotech Inc. (ONCY), ORIC Pharmaceuticals, Inc. (ORIC), Puma Biotechnology, Inc. (PBYI), PMV Pharmaceuticals, Inc. (PMVP), Replimune Group, Inc. (REPL), Relay Therapeutics, Inc. (RLAY), Revolution Medicines, Inc. (RVMD), Syndax Pharmaceuticals, Inc. (SNDX), Shattuck Labs, Inc. (STTK), Tango Therapeutics, Inc. (TNGX), Tyra Biosciences, Inc. (TYRA), Verastem, Inc. (VSTM), Zai Lab Limited (ZLAB), Zentalis Pharmaceuticals, Inc. (ZNTL). The market map groups them by business vertical — Clinical-stage oncology drug developers: 51 companies (RVMD, ONC, INCY, EXEL, COGT, CELC, RLAY, TNGX, IDYA, ZLAB, ELVN, IMNM, NBTX, SNDX, INBX, NUVB, AAPG, IMCR, ORIC, AVBP, TYRA, REPL, CADL, IMMP, GERN, VSTM, NVCT, PBYI, STTK, KURA, AGEN, GLUE, FENC, AURA, OLMA, KPTI, IPHA, IMRX, GNLX, ONCY, ALXO, BBOT, CHRS, BYSI, CRDF, ZNTL, BDTX, ACTU, ARVN, CRBP, PMVP); Large-cap diversified oncology franchises: 2 companies (AMGN, BMY); Commercial-stage specialty oncology and supportive care: 1 company (HCM). 31 of the 54 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

What was excluded and why

252 records failed a validation gate and never feed a statistic in this report (219 excluded from aggregate; 33 quarantined). Each exclusion, with its reason: AAPG — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · AAPG — Implied EBITDA margin 82.6% outside the plausible band [-100%, 80%] (effect: quarantined) · AAPG — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ACTU — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ACTU — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ACTU — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ACTU — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AGEN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AGEN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AGEN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ALXO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ALXO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ALXO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ALXO — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ARVN — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ARVN — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ARVN — Implied EBITDA margin -331.7% outside the plausible band [-100%, 80%] (effect: quarantined) · ARVN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ARVN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ARVN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ARVN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AURA — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AURA — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AURA — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AURA — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · further items are listed in the companion tables.

Primary valuation basis and how it was chosen

Primary valuation basis: EV / Revenue on CY2027E consensus (31 of 54 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (33 of 54 companies), so this report follows it. EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Oncology Therapeutics and it clears the coverage gate with 31 of 54 companies (57%). P / E is carried as a cross-check. A revenue lens is used rather than a profit multiple because the set is not consistently profitable on a forward basis (6 of 54 names with a meaningful EBITDA). The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 6 of 54 companies; EV / rEVenue: 43 of 54 companies; P/E: 8 of 54 companies. 3 companies show a non-meaningful EV / EBITDA denominator and are excluded from that statistic. 38 companies show a non-meaningful P / E denominator and are excluded from that statistic.

How the multiples and statistics are computed

Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥6.5x, Core 2.1x–6.5x, Discount <2.1x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 3.5x = median(ev_revenue CY2027E) (31 rated companies) · 19.5x = median(ev_revenue CY2027E) within Premium tier (n=8) · 3.5x = median(ev_revenue CY2027E) within Core tier (n=15) · 1.7x = median(ev_revenue CY2027E) within Discount tier (n=8) · 3.2x = median(ev_revenue CY2027E) | growth ≥ 15% (n=12) · 4.2x = median(ev_revenue CY2027E) | growth < 15% (n=12) · 38% = median Rule of 40 score (revenue growth + EBITDA margin) (n=5)

Precedent transactions: what is in the record and why

The precedent record holds the M&A transactions in Oncology Therapeutics recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 86 transactions were recorded for this industry; 28 are shown. 58 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 36 × deal value unit unresolved; 55 × no evidence record; 6 × duplicate precedent id. Case studies lead with the 3 richest stories — disclosed value, a readable multiple, newest first.

Sources

Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 1190 source documents stand behind this report; by publisher domain: sec.gov (1185), home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.

Interpretation and important notice

Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.

Sources linked in the report

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Oncology Therapeutics?

Company valuation reports run the same method against a single business — public or private.